Last checked at 11 Apr 2024 17:13
FTSE 100 edges lower as financials drag
Lok'nStore surges to all-time high after buyout by Shurgard
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades16,417
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,050.00
Bid:
12,038.00
Ask:
12,040.00
Change:
-106.00 (-0.87%)
Spread:
2.00 (0.017%)
Open:
12,092.00
High:
12,178.00
Low:
12,010.00
Prev. Close:
12,156.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.London pre-open: Chinese PMI data to drag FTSE lower early on
Sun, 02nd Nov 2014 17:33
Tracking a weaker session in Asia overnight, UK stocks are expected to begin a macro-focused week with small gains.City sources predict the FTSE 100 will open around nine points lower than Friday's close of 6,546.47."As we approach a major week in the markets in terms of economic events, we are likely to see more caution creep in as traders seek to gain their sentiment through the various releases throughout the week," said Alpari market analyst Joshue Mahony.The weakness is largely due to the slowdown seen in Chinese manufacturing growth in October that was announced on Saturday.According the National Bureau of Statistics, the country's official purchasing managers index (PMI) dropped to 50.8 from 51.1 in September, although this was marginally higher than the figure of 50.4 that was given by HSBC on Monday morning."The fact of the matter is that the one sector that matters is manufacturing, yet for two and a half years, the sector has failed to gain any sort of meaningful traction, with a peak of 51.7 compared to a reading of 59.2 recorded in mid-2008," Mahony said.The news reversed gains seen on Friday, which came after Japan announced it will put half of its holdings in local and foreign stocks, doubling previous levels, and invest in alternative assets.The Bank of Japan last week raised its annual target for monetary expansion to 80trn yen ($724bn) from 70trn yen.Closer to home, both the US and Europe will both also see the release of manufacturing PMI data in Monday's session, with readings from the latter expected to be mixed.In company news, Diageo has agreed on an asset-swap deal with Casa Cuervo which will see the UK spirits group take full control of tequila label Don Julio in exchange for selling its Bushmills whisky brand. The deal, which also involves the early termination of Case Cuervo's production and distribution agreement for Smirnoff in Mexico, will result in a net payment of $408m to Diageo on completion.Drugs maker Astrazeneca has completed the transfer of the development and commercialisation rights to Almirall's respiratory franchise, paying an initial $875m, plus up to a further $1.22bn in development, launch and sales-related milestones. The deal is expected to be neutral to core earnings per share in 2015 and accretive from 2016.Ryanair's first half profits flew 32% higher to €795m on Monday thanks to a strong summer and the budget airline's customer charm offensive, involving the introduction of allocated seating, extra free hand baggage and new initiatives to lure business travellers.
More News
11 Apr 2024 17:07
Banks weigh down Europe's STOXX 600 after ECB signals rate cuts
Outlook hike sends Ambu shares up
*Read more11 Apr 2024 15:56
London close: Stocks finish lower as ECB stands pat
(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.
Read more11 Apr 2024 11:50
LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision
(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.
Read more11 Apr 2024 08:56
TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023
(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.
Read more11 Apr 2024 08:54
LONDON MARKET OPEN: European markets mixed ahead of ECB decision
(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.
Read more11 Apr 2024 07:49
LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance
(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.
Read more11 Apr 2024 07:20
AstraZeneca to hike 2024 dividend by 7%
(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.
Read more8 Apr 2024 08:36
TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris
(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.
Read more8 Apr 2024 07:43
LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack
(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.
Read more8 Apr 2024 07:02
AstraZeneca's Enhurtu cancer gets US green light for adult patients
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.
Read more8 Apr 2024 06:53
TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.
Read more5 Apr 2024 09:42
AstraZeneca makes "breakthrough" in treating small cell lung cancer
(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.
Read more5 Apr 2024 07:50
LONDON BRIEFING: Shell to book USD600 million first-quarter write-off
(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.
Read more5 Apr 2024 07:23
AstraZeneca announces positive lung cancer treatment trial results
(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.
Read more